PAVmed (FRA:1P5) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1P5 PAVmed Inc FRA:1P5
35 GF Score
Price €4.13
GF Value €0.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PAVmed 5-Year Yield-on-Cost %?

PAVmed FRA:1P5 -2.25% 35 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus rates FRA:1P5 with a GF Score™ of 35/100 and a GF Value™ of €0.93 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 318 Medical Devices & Instruments companies, PAVmed ranks worse than 314465.09% on this metric.

PAVmed's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for PAVmed's 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:1P5's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.435
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

PAVmed  (FRA:1P5) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


PAVmed 5-Year Yield-on-Cost % Related Terms


FRA:1P5 vs BDMD, NSPR, TELA: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, PAVmed's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where PAVmed's 5-Year Yield-on-Cost % falls into.


FRA:1P5
35GF Score
PAVmed Inc FRA:1P5
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PAVmed 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of PAVmed is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
PAVmed (FRA:1P5) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PAVmed and its competitors. According to the industry distribution chart, PAVmed ranks #999999 out of 318 companies in the Medical Devices & Instruments industry.
Is PAVmed's 5-Year Yield-on-Cost % too high?
PAVmed's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, PAVmed ranks #999999 out of 318 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PAVmed has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PAVmed's 5-Year Yield-on-Cost % compare to BDMD and NSPR?
According to the Medical Devices & Instruments industry distribution chart, PAVmed ranks #999999 out of 318 companies for 5-Year Yield-on-Cost %. This places PAVmed in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PAVmed and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PAVmed's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
Based on GuruFocus' analysis, PAVmed (FRA:1P5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.93, compared to a current price of €4.13 — trading 343.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. PAVmed's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PAVmed (FRA:1P5), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PAVmed (FRA:1P5) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of €4.13 is trading 343.5% above its estimated GF Value™ of €0.93. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for FRA:1P5:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €0.93 vs. price of €4.13 (343.5% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PAVmed Business Description

Other Exchanges PAVM:USA
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
35GF Score

Get the complete analysis for FRA:1P5

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€0.93
GF Value